Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
By Michael D. Williamson
Feb. 19 — The merry-go-round of health-care association leadership continues, as Scott Whitaker, an executive with a biotech lobby group, was named the new president and CEO of the Advanced Medical Technology Association, a device industry group.
Whitaker was the Biotechnology Innovation Organization's chief operating officer. He'll start his new position at AdvaMed April 4.
He takes over for Stephen Ubl, who left the device group last fall to be the head of the pharmaceutical trade group Pharmaceutical Research and Manufacturers of America (13 PLIR 1429, 10/2/15).
Whitaker also served in leadership roles at the Department of Health and Human Services, including as chief of staff and assistant secretary for legislation.
AdvaMed's Board of Directors announced Whitaker's appointment in a Feb. 18 statement.
“It is a tremendous privilege to join AdvaMed and represent such an innovative and life changing industry,” Whitaker said in the statement. “Given the many health care challenges throughout the world, it is critical that we work together to create a policy and regulatory environment that will allow this industry to continue to discover, develop and deliver innovative medical technologies to patients.”
AdvaMed Board Chairman Vincent A. Forlenza, chairman, CEO and president of the device firm BD, said in the release, “We are very pleased that Scott has agreed to lead AdvaMed at a time of unprecedented change in health care.”
Medical technology companies are at the forefront of developing solutions that improve patient outcomes and enable the delivery of high-quality, cost-effective care, Forlenza said. Continued progress in these areas depends on ensuring a strong innovation ecosystem and “Scott has a proven track record as an association leader, and we believe he has the vision to set the course for AdvaMed's future,” he said.
In a separate Feb. 18 statement, Jim Greenwood, president and chief executive officer at BIO, praised Whitaker's tenure at the group. “During his 11-plus years at BIO, Scott has provided our organization with strong, steady, collegial and creative leadership,” Greenwood said.
Greenwood added that Whitaker “has been a trusted advisor throughout my tenure” and while he will be missed, part of his legacy will be the deep bench of talent he helped to build and cultivate at every level of BIO.
To contact the reporter on this story: Michael D. Williamson in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)